Tags

Type your tag names separated by a space and hit enter

A drug safety evaluation of mirabegron in the management of overactive bladder.
Expert Opin Drug Saf. 2016 May; 15(5):689-96.EO

Abstract

INTRODUCTION

Overactive Bladder (OAB) is a clinical syndrome describing the symptom complex of urgency, with or without urgency incontinence and is usually associated with frequency and nocturia. Antimuscarinics are currently the most widely prescribed drugs for OAB although persistence with medication is often limited due to lack of efficacy or intolerable adverse effects. Mirabegron is β3 adrenoreceptor agonist that is the first new drug licensed for the management of overactive bladder (OAB) in over 30 years.

AREAS COVERED

This review provides a comprehensive overview of the mirabegron clinical trials programme, including Phase II, III and IV studies with a particular focus on tolerability and safety. A literature search was performed in Pubmed using the key words 'mirabegron', 'overactive bladder', 'β3 adrenoceptor agonist' and 'detrusor overactivity' with no restriction on dates.

EXPERT OPINION

The extensive clinical trial programme has shown mirabegron to be safe and efficacious in the treatment of OAB symptoms and the evidence would suggest that it offers an effective alternative to antimuscarinic therapy.

Authors+Show Affiliations

a Department of Urogynaecology , Kings College Hospital , London , UK.a Department of Urogynaecology , Kings College Hospital , London , UK.a Department of Urogynaecology , Kings College Hospital , London , UK.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

26980445

Citation

Robinson, Dudley, et al. "A Drug Safety Evaluation of Mirabegron in the Management of Overactive Bladder." Expert Opinion On Drug Safety, vol. 15, no. 5, 2016, pp. 689-96.
Robinson D, Thiagamoorthy G, Cardozo L. A drug safety evaluation of mirabegron in the management of overactive bladder. Expert Opin Drug Saf. 2016;15(5):689-96.
Robinson, D., Thiagamoorthy, G., & Cardozo, L. (2016). A drug safety evaluation of mirabegron in the management of overactive bladder. Expert Opinion On Drug Safety, 15(5), 689-96. https://doi.org/10.1517/14740338.2016.1165663
Robinson D, Thiagamoorthy G, Cardozo L. A Drug Safety Evaluation of Mirabegron in the Management of Overactive Bladder. Expert Opin Drug Saf. 2016;15(5):689-96. PubMed PMID: 26980445.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A drug safety evaluation of mirabegron in the management of overactive bladder. AU - Robinson,Dudley, AU - Thiagamoorthy,Ganesh, AU - Cardozo,Linda, Y1 - 2016/04/21/ PY - 2016/3/17/entrez PY - 2016/3/17/pubmed PY - 2017/1/31/medline KW - Mirabegron KW - overactive bladder KW - urinary incontinence KW - β3 adrenoceptor agonist SP - 689 EP - 96 JF - Expert opinion on drug safety JO - Expert Opin Drug Saf VL - 15 IS - 5 N2 - INTRODUCTION: Overactive Bladder (OAB) is a clinical syndrome describing the symptom complex of urgency, with or without urgency incontinence and is usually associated with frequency and nocturia. Antimuscarinics are currently the most widely prescribed drugs for OAB although persistence with medication is often limited due to lack of efficacy or intolerable adverse effects. Mirabegron is β3 adrenoreceptor agonist that is the first new drug licensed for the management of overactive bladder (OAB) in over 30 years. AREAS COVERED: This review provides a comprehensive overview of the mirabegron clinical trials programme, including Phase II, III and IV studies with a particular focus on tolerability and safety. A literature search was performed in Pubmed using the key words 'mirabegron', 'overactive bladder', 'β3 adrenoceptor agonist' and 'detrusor overactivity' with no restriction on dates. EXPERT OPINION: The extensive clinical trial programme has shown mirabegron to be safe and efficacious in the treatment of OAB symptoms and the evidence would suggest that it offers an effective alternative to antimuscarinic therapy. SN - 1744-764X UR - https://www.unboundmedicine.com/medline/citation/26980445/A_drug_safety_evaluation_of_mirabegron_in_the_management_of_overactive_bladder_ L2 - https://www.tandfonline.com/doi/full/10.1517/14740338.2016.1165663 DB - PRIME DP - Unbound Medicine ER -